Kirouac, Daniel C

Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors. [electronic resource] - Science signaling Aug 2013 - ra68 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1937-9145

10.1126/scisignal.2004008 doi


Animals
Antibodies, Bispecific
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols--pharmacology
Biomarkers, Tumor--metabolism
Breast Neoplasms--drug therapy
Computer Simulation
Feedback, Physiological--physiology
Female
Lapatinib
MAP Kinase Signaling System--drug effects
Mice
Models, Biological
Neuregulin-1
Oncogene Protein v-akt--antagonists & inhibitors
Quinazolines
Receptor, ErbB-2--antagonists & inhibitors
Receptor, ErbB-3--antagonists & inhibitors
Signal Transduction--physiology
Trastuzumab